NCT02106975

Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 170 (actual)
• Sponsor: Virginia Commonwealth University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Hypothesis 1A: Vitamin C infusion will significantly attenuate sepsis-induced systemic organ failure as measured by Sequential Organ Failure Assessment (SOFA) score, Hypothesis 1B: Vitamin C infusion will attenuate sepsis-induced lung injury as assessed by the oxygenation index and the VE40 Hypothesis 1C: Vitamin C infusion will attenuate biomarkers of inflammation (C-Reactive Protein, Procalcitonin), vascular injury (Thrombomodulin, Angiopoietin-2), alveolar epithelial injury (Receptor for Advanced Glycation Products), while inducing the onset of a fibrinolytic state (Tissue Factor Pathway Inhibitor).

Conditions

• Acute Lung Injury
• Sepsis

Interventions

Type	Name	Description
DRUG	Ascorbic Acid	Intervention
DRUG	Placebo: 5% Dextrose in water	Placebo

Timeline

• Start date: 2014-04-01
• Primary completion: 2017-11-16
• Completion: 2018-01-08
• First posted: 2014-04-08
• Last updated: 2019-10-15
• Results posted: 2019-10-15

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated drug study